DOSSIER · 13F-HR · Q2 2026

REGENERON PHARMACEUTICALS, INC.

$177M in tracked AUM across 3 positions as of Q2 2026.

RP
CIK 0000872589 · last filed Jun 30, 2026
Total AUM
$177M
as of Q2 2026
Holdings
3
positions
Whale Score
71
71
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

The SEC 13F filing for Regeneron Pharmaceuticals, Inc. (CIK: 0000872589) reveals a highly concentrated investment portfolio managed with a distinct strategic focus. As of the reporting date September 30, 2025, the total portfolio value stands at approximately $699.66 million. This represents a significant decrease of 52.9% from the previous quarter's value of $1.49 billion. The portfolio consists of only three holdings, indicating an aggressive concentration strategy rath...

Key Holdings

The portfolio is dominated by positions in the biotechnology and gene therapy sectors, reflecting Regeneron's core industry expertise.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
PBLS
Parabilis Medicines, Inc.
$114M4.2M64.4%
02
NTLA
Intellia Therapeutics, Inc.
$63M3.7M35.4%
03
ACET
Adicet Bio, Inc.
$523K61K0.3%

Filing history

2026Q2Jun 30
$177M 270.1%
3 positionsView →
2026Q1Mar 31
$48M 41.7%
2 positionsView →
2025Q4Dec 31
$34M 95.2%
2 positionsView →
2025Q3Sep 30
$700M 52.9%
3 positionsView →
2025Q2Jun 30
$1.5B 21.0%
4 positionsLocked
2025Q1Mar 31
$1.2B 12.1%
4 positionsLocked
2024Q4Dec 31
$1.1B
6 positionsLocked